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Paul Nurse: cycling up
the hill
Matthijs J. Smith
Combining primary research with the
administrative demands of a senior
position in science is a tricky
balancing act. But Paul Nurse, who
has recently been appointed Director
General of the UK’s prestigious
research organization, the Imperial
Cancer Research Fund (ICRF),
certainly has no intention of retiring
behind a desk. His promotion from
Director of Laboratory Research
promises to bring exciting times to
the ICRF. With his background in the
fundamental research that has
revolutionized our understanding of
the cell cycle, and his commitment to
continuing his primary research,
Nurse will be directing the ICRF into
the next century clutching a petri dish
in one hand.
Nurse was brought up in a North
London working-class household and
was the only one of four children to
carry on education beyond school.
After completing secondary
education, he worked for a year in the
Guinness Brewery laboratories, where
he was first introduced to large-scale
screening procedures. This
consolidated his interest in biology,
which he went on to study at
Birmingham University. After
graduating with Honours, he moved
to the University of East Anglia for his
doctorate, to study the intracellular
localization of molecules during cell
division. A large part of this work
involved baby-sitting a
temperamental amino-acid analyzer,
which often required attention into
the small hours of the night. During
one of these nocturnal vigils, he
recalls reading a paper by Lee
Hartwell describing how genetics
could be used to study the cell cycle
in budding yeast. Nurse was inspired
by the elegant use of genetics to study
a fundamental process and wanted to
try a similar approach in fission yeast.
But there were a couple of problems:
he knew not a great deal about yeast
and even less about genetics.
Nurse contacted Murdoch
Mitchison, a prominent fission yeast
physiologist in Edinburgh, who
agreed that this was a very exciting
approach but one that would require
Nurse to learn some yeast genetics.
Nurse was given funding for six
months from the Royal Society to
learn these techniques from Urs
Leupold in Bern, Switzerland. In
1974, Nurse joined Mitchison’s lab
and began screening for mutated
yeast strains that divided abnormally.
The first mutant was soon identified
and isolated on the basis of its small
size during cell division (with a dash
of his infamous humour, he wanted to
christen it wee1, ‘wee’ being Scots for
tiny). Nurse continued to expand his
collection of mutant strains and used
genetic techniques to identify the
network of genes controlling the
fission yeast cell cycle. Mitchison’s lab
soon became a meeting point for
other cell cyclers, such as Kim
Nasmyth, who did his doctoral
research with Nurse, and Peter
Fantes and Pierre Thuriaux, who
were interested in the regulation of
cell-size control.
In the late 1970s, techniques were
developed for transforming budding
yeast with exogenous DNA.
Unfortunately, this technology —
which would have allowed Nurse to
isolate the actual genes mutated in his
yeast strains — was not available for
fission yeast. Never one to fight shy of
a problem, Nurse moved to the
University of Sussex to establish
methods for transforming fission
yeast. This was a long and arduous
task but, with the help of David
Beach, he got the technique working
and used it to isolate the cdc2 gene
from one of his strains.
In 1984, Nurse joined the ICRF
laboratories in London. Although the
ICRF was initially interested in the
use of yeast purely as a eukaryotic
gene expression system, Nurse soon
convinced them of the importance of
studies in yeast for understanding the
mammalian cell cycle. Using DNA-
hybridization techniques, he began
hunting for mammalian homologues
of his yeast cell-cycle genes, with little
success. Nurse recalls thinking it was
worth one last shot, and in 1986 he
and postdoc Melanie Lee attempted
to functionally complement one of
their yeast mutants with a library of
human cDNAs. Remarkably, it
worked, and soon they had isolated
the human cdc2 homologue.
Despite his success and the
abundant facilities available to him at
the ICRF, Nurse took up the post of
Iveagh Professor of Microbiology at
Oxford in 1987, in a move largely
inspired by the better lifestyle Oxford
offered his family. His lab grew in
size, partly because of an influx of
American postdocs attracted by both
the excellence of the science and the
deserved reputation of ‘the wee one’
for fairness and frivolity. Then, in
1993, Nurse returned to the ICRF in
London as the Director of Laboratory
Research. Although taking a position
with such heavy administrative
responsibilities seemed like a
surprising move for a ‘hands on’
scientist, the organizational structure
of the ICRF has allowed him to spend
up to half his time in the laboratory.
When Nurse moves into the Director-
General’s chair this month, he will
continue to cycle his energies
between the lab and the office.
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High flyer Paul Nurse, ready for take-off.
